Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Missov, R. M.
Right arrow Articles by Grobbee, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Missov, R. M.
Right arrow Articles by Grobbee, D. E.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 19, Issue 2 157-159, Copyright © 1996 by American Diabetes Association

ARTICLES

Plasma fibrinogen in NIDDM: the Rotterdam study

RM Missov, RP Stolk, JG van der Bom, A Hofman, ML Bots, HA Pols and DE Grobbee
Department of Epidemiology and Biostatistics, Erasmus University Medical School, Netherlands.

OBJECTIVE: To compare plasma fibrinogen levels across groups of subjects with and without NIDDM with respect to diabetes therapy and to evaluate the influence of metabolic control and other selected factors. RESEARCH DESIGN AND METHODS: In a cross-sectional study, plasma fibrinogen was measured in 2,971 elderly subjects aged 55 years and older (mean age 70.8 years). This was part of the baseline examination of the Rotterdam Study, a population-based study of chronic diseases in the elderly. RESULTS: Plasma fibrinogen levels did not differ among subjects with and without NIDDM (2.84 vs. 2.81 milligrams, P = 0.5). After adjustment for age, sex, smoking, BMI, and waist-to-hip ratio, the plasma fibrinogen levels were higher in subjects receiving insulin therapy. In those without diabetes (n = 2,640), with diabetes but not taking antidiabetes medication (n = 196), taking oral medication (n = 99), and taking insulin (n = 36), the age- and sex-adjusted fibrinogen levels were 2.82 (SE 0.01), 2.79 (0.05), 2.79 (0.07), and 3.23 (0.11) milligrams, respectively (P < 0.005). Adjustment for leukocyte count or serum creatinine level did not affect the observed association, while adjustment for fructosamine decreased the differences. CONCLUSIONS: Plasma fibrinogen levels are elevated in insulin-treated NIDDM patients, which may reflect worse metabolic control in this subgroup.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
K.-H. Mak and D. P. Faxon
Clinical studies on coronary revascularization in patients with type 2 diabetes
Eur. Heart J., June 2, 2003; 24(12): 1087 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. L. Klein, S. J. Hunter, A. J. Jenkins, D. Zheng, A. J. Semler, J. Clore, W. T. Garvey, and The DCCT/EDIC Study Group
Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort
Diabetes Care, May 1, 2003; 26(5): 1439 - 1448.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Barazzoni, M. Zanetti, G. Davanzo, E. Kiwanuka, P. Carraro, A. Tiengo, and P. Tessari
Increased Fibrinogen Production in Type 2 Diabetic Patients without Detectable Vascular Complications: Correlation with Plasma Glucagon Concentrations
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3121 - 3125.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
I. Saito, A. R. Folsom, F. L. Brancati, B. B. Duncan, L. E. Chambless, and P. G. McGovern
Nontraditional Risk Factors for Coronary Heart Disease Incidence among Persons with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
Ann Intern Med, July 18, 2000; 133(2): 81 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. R. Folsom, K. K. Wu, M. Rasmussen, L. E. Chambless, N. Aleksic, and F. J. Nieto
Determinants of Population Changes in Fibrinogen and Factor VII Over 6 Years : The Atherosclerosis Risk in Communities (ARIC) Study
Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 601 - 606.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. B. Meigs, M. A. Mittleman, D. M. Nathan, G. H. Tofler, D. E. Singer, P. M. Murphy-Sheehy, I. Lipinska, R. B. D'Agostino, and P. W. F. Wilson
Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis: The Framingham Offspring Study
JAMA, January 12, 2000; 283(2): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Festa, R. D'Agostino Jr, L. Mykkanen, R. P. Tracy, D. J. Zaccaro, C. N. Hales, and S. M. Haffner
Relative Contribution of Insulin and Its Precursors to Fibrinogen and PAI-1 in a Large Population With Different States of Glucose Tolerance : The Insulin Resistance Atherosclerosis Study (IRAS)
Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 562 - 568.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
N. Emanuele, N. Azad, C. Abraira, W. Henderson, J. Colwell, S. Levin, F. Nuttall, J. Comstock, C. Sawin, C. Silbert, et al.
Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus
Arch Intern Med, December 1, 1998; 158(22): 2485 - 2490.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1996 by the American Diabetes Association.